But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

Piper Sandler raised the firm’s price target on Amgen (AMGN) to $329 from $310 and keeps an Overweight rating on the shares. The firm notes the ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Amgen in a research note issued to ...

The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...

Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key ...

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...

Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance ...

Investment analysts at William Blair reduced their FY2025 earnings per share estimates for Amgen in a report released on Wednesday, February 5th. William Blair analyst M. Phipps now anticipates that ...

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...